GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » EV-to-Revenue

HAEMATO AG (XTER:HAEK) EV-to-Revenue : 0.34 (As of May. 12, 2024)


View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HAEMATO AG's enterprise value is €88.6 Mil. HAEMATO AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €260.8 Mil. Therefore, HAEMATO AG's EV-to-Revenue for today is 0.34.

The historical rank and industry rank for HAEMATO AG's EV-to-Revenue or its related term are showing as below:

XTER:HAEK' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.14   Med: 0.4   Max: 3.38
Current: 0.21

During the past 13 years, the highest EV-to-Revenue of HAEMATO AG was 3.38. The lowest was 0.14. And the median was 0.40.

XTER:HAEK's EV-to-Revenue is ranked better than
96.98% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.41 vs XTER:HAEK: 0.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), HAEMATO AG's stock price is €21.40. HAEMATO AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €50.10. Therefore, HAEMATO AG's PS Ratio for today is 0.43.


HAEMATO AG EV-to-Revenue Historical Data

The historical data trend for HAEMATO AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG EV-to-Revenue Chart

HAEMATO AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.32 0.41 0.32 0.24

HAEMATO AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.32 - 0.24 -

Competitive Comparison of HAEMATO AG's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HAEMATO AG's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's EV-to-Revenue falls into.



HAEMATO AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

HAEMATO AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=88.594/260.808
=0.34

HAEMATO AG's current Enterprise Value is €88.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HAEMATO AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €260.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HAEMATO AG  (XTER:HAEK) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

HAEMATO AG's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=21.40/50.099
=0.43

HAEMATO AG's share price for today is €21.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was €50.10.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HAEMATO AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


HAEMATO AG (XTER:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines